Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.

ABSTRACT:

Aim

To report the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) versus standard-of-care basal insulin analogues (SOC-BI) at 12 months in the ACHIEVE Control trial, which is a prospective pragmatic randomized real-life study in insulin-naïve adults with type 2 diabetes (T2D).

Methods

A total of 3304 insulin-naïve adults with T2D and glycated haemoglobin (HbA1c) concentration of 64 to 97 mmol/mol (8.0% to 11.0%) after ≥1 year of treatment with two or more antihyperglycaemic agents were randomized to Gla-300 or SOC-BI. Key secondary endpoints included HbA1c target attainment without documented symptomatic (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia at 12 months.

Results

At 12 months, 26.1% (Gla-300) and 23.7% (SOC-BI) of adults achieved HbA1c targ

SUBMITTER: Meneghini L 

PROVIDER: S-EPMC7689721 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature